LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Pictilisib | 1.11 | uM | LJP6 | 72 | hr | 868 | 2542 | 3556 | 0.7144 | 0.6946 |
MDA-MB-231 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2550 | 3556 | 0.7180 | 0.6992 |
MDA-MB-231 | Pictilisib | 10 | uM | LJP6 | 72 | hr | 868 | 1806 | 3556 | 0.5087 | 0.4343 |
MDA-MB-231 | PD184352 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3587 | 3410 | 1.0514 | 1.0513 |
MDA-MB-231 | PD184352 | 0.12 | uM | LJP5 | 72 | hr | 868 | 2957 | 3410 | 0.8667 | 0.8593 |
MDA-MB-231 | PD184352 | 0.37 | uM | LJP5 | 72 | hr | 868 | 2608 | 3410 | 0.7646 | 0.7450 |
MDA-MB-231 | PD184352 | 1.11 | uM | LJP5 | 72 | hr | 868 | 2132 | 3410 | 0.6244 | 0.5739 |
MDA-MB-231 | PD184352 | 3.33 | uM | LJP5 | 72 | hr | 868 | 1861 | 3410 | 0.5455 | 0.4703 |
MDA-MB-231 | PD184352 | 10 | uM | LJP5 | 72 | hr | 868 | 1359 | 3410 | 0.3991 | 0.2555 |
MDA-MB-231 | PLX-4720 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3516 | 3410 | 1.0307 | 1.0301 |
MDA-MB-231 | PLX-4720 | 0.12 | uM | LJP5 | 72 | hr | 868 | 3613 | 3410 | 1.0591 | 1.0585 |
MDA-MB-231 | PLX-4720 | 0.37 | uM | LJP5 | 72 | hr | 868 | 3495 | 3410 | 1.0252 | 1.0248 |
MDA-MB-231 | PLX-4720 | 1.11 | uM | LJP5 | 72 | hr | 868 | 3032 | 3410 | 0.8890 | 0.8837 |
MDA-MB-231 | PLX-4720 | 3.33 | uM | LJP5 | 72 | hr | 868 | 2602 | 3410 | 0.7611 | 0.7380 |
MDA-MB-231 | PLX-4720 | 10 | uM | LJP5 | 72 | hr | 868 | 1683 | 3410 | 0.4931 | 0.3947 |
MDA-MB-231 | Lapatinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 3009 | 3556 | 0.8457 | 0.8414 |
MDA-MB-231 | Lapatinib | 0.12 | uM | LJP6 | 72 | hr | 868 | 3327 | 3556 | 0.9362 | 0.9364 |
MDA-MB-231 | Lapatinib | 0.37 | uM | LJP6 | 72 | hr | 868 | 3351 | 3556 | 0.9429 | 0.9429 |
MDA-MB-231 | Lapatinib | 1.11 | uM | LJP6 | 72 | hr | 868 | 3474 | 3556 | 0.9770 | 0.9773 |
MDA-MB-231 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 3373 | 3556 | 0.9480 | 0.9475 |
MDA-MB-231 | Lapatinib | 10 | uM | LJP6 | 72 | hr | 868 | 2607 | 3556 | 0.7340 | 0.7180 |
MDA-MB-231 | Sirolimus | 0.04 | uM | LJP6 | 72 | hr | 868 | 2868 | 3556 | 0.8076 | 0.8006 |
MDA-MB-231 | Sirolimus | 0.12 | uM | LJP6 | 72 | hr | 868 | 2728 | 3556 | 0.7672 | 0.7556 |
MDA-MB-231 | Sirolimus | 0.37 | uM | LJP6 | 72 | hr | 868 | 2974 | 3556 | 0.8356 | 0.8300 |
MDA-MB-231 | Sirolimus | 1.11 | uM | LJP6 | 72 | hr | 868 | 2714 | 3556 | 0.7631 | 0.7508 |